Somatostatin vs DADLE
Head-to-head comparison of Somatostatin (Somatostatin-14) and DADLE ([D-Ala2, D-Leu5]-enkephalin) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Somatostatin | DADLE |
|---|---|---|
| Category | Pain Management | Pain Management |
| Full Name | Somatostatin-14 | [D-Ala2, D-Leu5]-enkephalin |
| Molecular Weight | 1637.85 | 569.67 Da |
| Half-Life | 1-3 min | 5-20 minutes in plasma |
| Amino Acids | 14 | 5 |
| Typical Dose | N/A|N/A | 0.01-2 ug per animal |
| Route | IV/SC | Intrathecal / intracerebroventricular |
| Purity | ≥98% | ≥98% |
| Studies Count | 84 | 450 |
| Research Status | Approved | Pre-clinical |
Somatostatin Benefits
- ✓nociceptive inhibition
- ✓anti-inflammatory signaling
- ✓visceral pain modulation
DADLE Benefits
- ✓delta-opioid agonism
- ✓enhanced peptide stability
- ✓spinal analgesia models
- ✓research on tolerance mechanisms
Somatostatin Dosing
N/A|N/A
DADLE Dosing
Intrathecal 0.01-2 ug per animal|Intracerebroventricular 0.01-1 ug per animal|In vitro 0.1-50 nM
Somatostatin Side Effects
- ⚠hyperglycemia
- ⚠bradycardia
- ⚠GI upset
DADLE Side Effects
- ⚠sedation
- ⚠motor suppression at higher doses
- ⚠opioid tolerance with repeated exposure
Research Overview
Somatostatin
Somatostatin reduces release of multiple excitatory mediators and can suppress pain signaling in preclinical and limited translational work. Its analgesic use is not standard, but the peptide is real and mechanistically relevant to pain control.
DADLE
DADLE has been studied for analgesic, neuroprotective, and receptor-selective opioid effects in animal and tissue models. It remains important as a mechanistic probe because it is more stable than endogenous enkephalins but still peptide-like in its delivery constraints.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.